Skip to Content
Merck
All Photos(1)

Key Documents

1708707

USP

Valproic acid

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

2-Propylpentanoic acid, Valproic acid

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
(CH3CH2CH2)2CHCO2H
CAS Number:
Molecular Weight:
144.21
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

valproic acid

manufacturer/tradename

USP

refractive index

n20/D 1.425 (lit.)

bp

220 °C (lit.)

density

0.9 g/mL at 25 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCCC(C(O)=O)CCC

InChI

1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)

InChI key

NIJJYAXOARWZEE-UHFFFAOYSA-N

Gene Information

human ... ALDH5A1(7915)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Valproic acid USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Divalproex Sodium
  • Divalproex Sodium Delayed-Release Capsules
  • Divalproex Sodium Delayed-Release Tablets
  • Divalproex Sodium Extended-Release Tablets
  • Valproate Sodium Injection
  • Valproic Acid
  • Valproic Acid Capsules

Biochem/physiol Actions

Anticonvulsant that also has efficacy as a mood stabilizer in bipolar disorder

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

Signal Word

Danger

Hazard Statements

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Repr. 1A - Skin Irrit. 2

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

231.8 °F - closed cup

Flash Point(C)

111 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mattias Linde et al.
The Cochrane database of systematic reviews, 6(6), CD010611-CD010611 (2013-06-26)
Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an
Ivana Rosenzweig et al.
Neuroscience and biobehavioral reviews, 36(8), 1848-1856 (2012-06-02)
Neuropsychiatric medications that directly alter the epigenome, such as valproic acid, can under certain conditions reactivate critical developmental periods and thus impact adult neuroconnectivity. In animal models valproic acid was shown to inhibit the process of postnatal myelination and to
Florence I Roullet et al.
Neurotoxicology and teratology, 36, 47-56 (2013-02-12)
Valproic acid (VPA) is both an anti-convulsant and a mood stabilizer. Clinical studies over the past 40 years have shown that exposure to VPA in utero is associated with birth defects, cognitive deficits, and increased risk of autism. Two recent
Radu M Nanau et al.
Clinical biochemistry, 46(15), 1323-1338 (2013-06-25)
Valproic acid is a widely-used first-generation antiepileptic drug, prescribed predominantly in epilepsy and psychiatric disorders. VPA has good efficacy and pharmacoeconomic profiles, as well as a relatively favorable safety profile. However, adverse drug reactions have been reported in relation with
Periyasamy Palsamy et al.
Experimental eye research, 121, 26-34 (2014-02-15)
Recent epidemiological studies confirm the prevalence of cataract in epileptic patients. Similarly, the drugs used to treat epilepsy also show the connection with increased cataract formation. In this present study, we investigated the suppression of Nrf2/Keap1 dependent antioxidant protection through

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service